By john abraham Nona Biosciences, a subsidiary of HBM Holdings Limited, stands at the forefront of biotechnology innovation with its pioneering approaches to antibody discovery and therapeutic development. Leveraging its proprietary Harbour Mice® platforms, nona biotechnology offers a comprehensive solution from the initial idea to investigational new drug (IND) application, emphasizing their commitment to transforming the landscape of biopharmaceutical research and development.
The Harbour Mice® technology is a cornerstone of Nona’s strategy, enabling the generation of fully human monoclonal antibodies through both traditional and unique heavy chain-only formats. This technology has facilitated the development of a wide array of biologic therapeutics, including bi-specific antibodies and antibody-drug conjugates, as well as advanced cell therapies like CAR-T and CAR-NK cells. The robustness of this platform is further evidenced by its clinical validation and widespread adoption across more than 50 corporate and academic partners globally, including industry giants like Moderna and Pfizer (NonaBio) (NonaBio).
Nona Biosciences not only excels in antibody generation but also provides integrated services covering the entire antibody discovery and development process. This includes antigen preparation, animal immunization, and single B cell screening, which are critical for ensuring the high specificity and efficacy of the antibodies produced. The company’s advanced engineering capabilities allow for further optimization of antibodies through techniques like affinity maturation and Fc engineering, ensuring they meet the stringent requirements of therapeutic applications (NonaBio) (NonaBio).
An example of Nona’s innovative collaborations includes their strategic partnership with Moderna, focusing on the development of nucleic acid-based immunotherapies for oncology. This collaboration utilizes Nona’s heavy chain-only antibody discovery platform to create novel therapeutics that are poised to make significant impacts in the treatment of cancer (NonaBio).
Nona Biosciences’ flexible business model, which facilitates access to its technologies for a diverse range of partners, underscores their commitment to democratizing biotechnology innovations. Their mission is to empower partners to drive biotherapeutic innovation, benefiting not only the biopharmaceutical industry but also patients worldwide by expediting the delivery of new and effective treatments (NonaBio).
For more information about Nona Biosciences and their revolutionary biotechnological solutions, you can visit their official website here.
